Novogyne Pharmaceuticals is a joint venture between Novartis Pharmaceuticals Corporation and Noven Pharmaceuticals, Inc. Since May 1998, Novogyne has been offering pharmaceutical products that enable physicians to better serve the medical needs of mature women. Novogyne's products include Vivelle-Dot^® (estradiol transdermal system), the #1 prescribed estrogen patch* and the smallest estrogen patch available, and CombiPatch^® (estradiol/norethindrone acetate transdermal system). With these advanced patches, Novogyne was the first company in the United States offering transdermal systems for both the estrogen-only and combination estrogen/progestin markets.

What Do We Offer You?

With the mature woman’s comfort in mind, Novogyne offers the most advanced and wearable transdermal patches on the market:

• Vivelle-Dot, a postage-stamp-sized advanced generation estrogen patch and the smallest estrogen patch available.
• CombiPatch, the first combination estrogen/progestin hormone therapy (HT) patch in the U.S.

The Novogyne Advantage

Novogyne's transdermal systems deliver drugs utilizing an adhesive patch containing medication. When adhered to the skin, medication is delivered through the tissues and into the bloodstream over an extended period of time. Novogyne’s patches utilize the patented DOT Matrix^® technology, which allows them to deliver more drug through a smaller patch area than any HT patches. DOT Matrix achieves this without compromising the patch’s ability to adhere. DOT Matrix patches adhere to the skin through normal activities, including showering, swimming, and exercise.

For more information on the DOT Matrix technology, click here.

DOT Matrix^® is a registered trademark of Noven Pharmaceuticals, Inc.

The information contained within this Web site is appropriate for U.S. residents only. A visit to this site should not replace a visit to your doctor.

*IMS Health^® National Prescription Audit Plus™, May 2011.